 | • レポートコード：MRC22NVL17463 • 出版社/出版日：LP Information / 2022年10月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療機器 |
| Single User | ￥541,680 (USD3,660) | ▷ お問い合わせ |
| Corporate User | ￥1,083,360 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界経済が回復するにつれて、2021年の女性向け尿失禁治療の成長は前年から大幅に変化します。LP Information社（米国）の最新の調査によると、世界の女性向け尿失禁治療市場規模は、2021年の000ドルから2022年には000ドルに達し、2021年～2022年間に000%の成長が予想されます。2028年には世界の女性向け尿失禁治療市場規模が000ドルまで成長し、調査期間中に000%の年平均成長率を記録すると予想されます。 米国の女性向け尿失禁治療市場は2021年に000ドルの市場規模が見込まれ、調査期間中は約000%の年平均成長率で成長すると予測されます。中国は世界の女性向け尿失禁治療市場の000%のシェアを占め、2028年までに000ドルに達すると展望されます。欧州の女性向け尿失禁治療の状況については、ドイツが2028年までに000ドルに達し、調査期間にわたって年平均成長率が000%になると予測されます。アジア地域では、日本と韓国の成長率が、今後5年間でそれぞれ000%と000%になると展望されます。 世界の主要な女性向け尿失禁治療プレーヤーとして、InControl Medical、 Uromems、 Johnson & Johnson、 Coloplast、 Boston Scientific、 BD、 Verity Medical、 Betatech Medical、 CL Medical、 Cousin Surgery、 Dipromed、 Ethicon、 Neomedic International、 Promedon、 THT Bio-science、 Condiner Medicalなどをカバーしています。売上の面では、世界のトップ2社が2021年に約000%市場シェアを占めています。 当レポートでは、製品タイプ、用途（アプリケーション）、主要メーカー、主要地域および国ごとの女性向け尿失禁治療市場の包括的な概要、市場シェア、および成長機会を掲載します。 タイプ別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ 尿道スリング、電気刺激装置、その他 用途（アプリケーション）別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ 婦人科クリニック、病院、外来手術センター 当レポートは次の地域と国の市場規模データを掲載します。 南北アメリカ（米国、カナダ、メキシコ、ブラジル） アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア） 欧州（ドイツ、フランス、イギリス、イタリア、ロシア） 中東/アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国） ********* 目次 ********* レポートの範囲 ・市場の紹介 ・分析対象期間 ・調査の目的 ・調査手法 ・調査プロセスおよびデータソース ・経済指標 ・通貨 エグゼクティブサマリー ・世界市場の概要：女性向け尿失禁治療の年間販売量2017-2028、地域別現状・将来分析 ・女性向け尿失禁治療のタイプ別セグメント：尿道スリング、電気刺激装置、その他 ・女性向け尿失禁治療のタイプ別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 ・女性向け尿失禁治療の用途別セグメント：婦人科クリニック、病院、外来手術センター ・女性向け尿失禁治療の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 企業別世界の女性向け尿失禁治療市場 ・企業別のグローバル女性向け尿失禁治療市場データ：2020-2022年の年間販売量、市場シェア ・企業別の女性向け尿失禁治療の年間売上：2020-2022年の売上、市場シェア ・企業別の女性向け尿失禁治療販売価格 ・主要企業の女性向け尿失禁治療生産地域、販売地域、製品タイプ ・市場集中度分析 ・新製品および潜在的な参加者 ・合併と買収、拡大 女性向け尿失禁治療の地域別レビュー ・地域別の女性向け尿失禁治療市場規模2017-2022：年間販売量、売上 ・主要国別の女性向け尿失禁治療市場規模2017-2022：年間販売量、売上 ・南北アメリカの女性向け尿失禁治療販売の成長 ・アジア太平洋の女性向け尿失禁治療販売の成長 ・欧州の女性向け尿失禁治療販売の成長 ・中東・アフリカの女性向け尿失禁治療販売の成長 南北アメリカ市場 ・南北アメリカの国別の女性向け尿失禁治療販売量、売上（2017-2022） ・南北アメリカの女性向け尿失禁治療の種類別販売量 ・南北アメリカの女性向け尿失禁治療の用途別販売量 ・米国の女性向け尿失禁治療市場 ・カナダの女性向け尿失禁治療市場 ・メキシコの女性向け尿失禁治療市場 ・ブラジルの女性向け尿失禁治療市場 アジア太平洋市場 ・アジア太平洋の国別の女性向け尿失禁治療販売量、売上（2017-2022） ・アジア太平洋の女性向け尿失禁治療の種類別販売量 ・アジア太平洋の女性向け尿失禁治療の用途別販売量 ・中国市場の女性向け尿失禁治療市場 ・日本市場の女性向け尿失禁治療市場 ・韓国市場の女性向け尿失禁治療市場 ・東南アジアの女性向け尿失禁治療市場 ・インドの女性向け尿失禁治療市場 ・オーストラリアの女性向け尿失禁治療市場 ・台湾の女性向け尿失禁治療市場 欧州市場 ・欧州の国別の女性向け尿失禁治療販売量、売上（2017-2022） ・欧州の女性向け尿失禁治療の種類別販売量 ・欧州の女性向け尿失禁治療の用途別販売量 ・ドイツの女性向け尿失禁治療市場 ・フランスの女性向け尿失禁治療市場 ・イギリスの女性向け尿失禁治療市場 ・イタリアの女性向け尿失禁治療市場 ・ロシアの女性向け尿失禁治療市場 中東・アフリカ市場 ・中東・アフリカの国別の女性向け尿失禁治療販売量、売上（2017-2022） ・中東・アフリカの女性向け尿失禁治療の種類別販売量 ・中東・アフリカの女性向け尿失禁治療の用途別販売量 ・エジプトの女性向け尿失禁治療市場 ・南アフリカの女性向け尿失禁治療市場 ・イスラエルの女性向け尿失禁治療市場 ・トルコの女性向け尿失禁治療市場 ・GCC諸国の女性向け尿失禁治療市場 市場の成長要因、課題、動向 ・市場の成長要因および成長機会分析 ・市場の課題およびリスク ・市場動向 製造コスト構造分析 ・原材料とサプライヤー ・女性向け尿失禁治療の製造コスト構造分析 ・女性向け尿失禁治療の製造プロセス分析 ・女性向け尿失禁治療の産業チェーン構造 マーケティング、販売業者および顧客 ・販売チャンネル：直接販売チャンネル、間接販売チャンネル ・女性向け尿失禁治療の主要なグローバル販売業者 ・女性向け尿失禁治療の主要なグローバル顧客 地域別の女性向け尿失禁治療市場予測レビュー ・地域別の女性向け尿失禁治療市場規模予測（2023-2028） ・南北アメリカの国別予測 ・アジア太平洋の国別予測 ・欧州の国別予測 ・女性向け尿失禁治療のタイプ別市場規模予測 ・女性向け尿失禁治療の用途別市場規模予測 主要企業分析 InControl Medical、 Uromems、 Johnson & Johnson、 Coloplast、 Boston Scientific、 BD、 Verity Medical、 Betatech Medical、 CL Medical、 Cousin Surgery、 Dipromed、 Ethicon、 Neomedic International、 Promedon、 THT Bio-science、 Condiner Medical ・企業情報 ・女性向け尿失禁治療製品 ・女性向け尿失禁治療販売量、売上、価格、粗利益（2020-2022） ・主要ビジネス概要 ・最新動向 調査結果および結論 |
As the global economy mends, the 2021 growth of Female Urinary Incontinence Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Female Urinary Incontinence Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Female Urinary Incontinence Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Female Urinary Incontinence Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Female Urinary Incontinence Treatment market, reaching US$ million by the year 2028. As for the Europe Female Urinary Incontinence Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Female Urinary Incontinence Treatment players cover InControl Medical, Uromems, Johnson & Johnson, and Coloplast, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Female Urinary Incontinence Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Urethral Sling
Electrical Stimulator
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Gynecology Clinic
Hospitals
Ambulatory Surgical Centers
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
InControl Medical
Uromems
Johnson & Johnson
Coloplast
Boston Scientific
BD
Verity Medical
Betatech Medical
CL Medical
Cousin Surgery
Dipromed
Ethicon
Neomedic International
Promedon
THT Bio-science
Condiner Medical
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Female Urinary Incontinence Treatment Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Female Urinary Incontinence Treatment by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Female Urinary Incontinence Treatment by Country/Region, 2017, 2022 & 2028
2.2 Female Urinary Incontinence Treatment Segment by Type
2.2.1 Urethral Sling
2.2.2 Electrical Stimulator
2.2.3 Other
2.3 Female Urinary Incontinence Treatment Sales by Type
2.3.1 Global Female Urinary Incontinence Treatment Sales Market Share by Type (2017-2022)
2.3.2 Global Female Urinary Incontinence Treatment Revenue and Market Share by Type (2017-2022)
2.3.3 Global Female Urinary Incontinence Treatment Sale Price by Type (2017-2022)
2.4 Female Urinary Incontinence Treatment Segment by Application
2.4.1 Gynecology Clinic
2.4.2 Hospitals
2.4.3 Ambulatory Surgical Centers
2.5 Female Urinary Incontinence Treatment Sales by Application
2.5.1 Global Female Urinary Incontinence Treatment Sale Market Share by Application (2017-2022)
2.5.2 Global Female Urinary Incontinence Treatment Revenue and Market Share by Application (2017-2022)
2.5.3 Global Female Urinary Incontinence Treatment Sale Price by Application (2017-2022)
3 Global Female Urinary Incontinence Treatment by Company
3.1 Global Female Urinary Incontinence Treatment Breakdown Data by Company
3.1.1 Global Female Urinary Incontinence Treatment Annual Sales by Company (2020-2022)
3.1.2 Global Female Urinary Incontinence Treatment Sales Market Share by Company (2020-2022)
3.2 Global Female Urinary Incontinence Treatment Annual Revenue by Company (2020-2022)
3.2.1 Global Female Urinary Incontinence Treatment Revenue by Company (2020-2022)
3.2.2 Global Female Urinary Incontinence Treatment Revenue Market Share by Company (2020-2022)
3.3 Global Female Urinary Incontinence Treatment Sale Price by Company
3.4 Key Manufacturers Female Urinary Incontinence Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Female Urinary Incontinence Treatment Product Location Distribution
3.4.2 Players Female Urinary Incontinence Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Female Urinary Incontinence Treatment by Geographic Region
4.1 World Historic Female Urinary Incontinence Treatment Market Size by Geographic Region (2017-2022)
4.1.1 Global Female Urinary Incontinence Treatment Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Female Urinary Incontinence Treatment Annual Revenue by Geographic Region
4.2 World Historic Female Urinary Incontinence Treatment Market Size by Country/Region (2017-2022)
4.2.1 Global Female Urinary Incontinence Treatment Annual Sales by Country/Region (2017-2022)
4.2.2 Global Female Urinary Incontinence Treatment Annual Revenue by Country/Region
4.3 Americas Female Urinary Incontinence Treatment Sales Growth
4.4 APAC Female Urinary Incontinence Treatment Sales Growth
4.5 Europe Female Urinary Incontinence Treatment Sales Growth
4.6 Middle East & Africa Female Urinary Incontinence Treatment Sales Growth
5 Americas
5.1 Americas Female Urinary Incontinence Treatment Sales by Country
5.1.1 Americas Female Urinary Incontinence Treatment Sales by Country (2017-2022)
5.1.2 Americas Female Urinary Incontinence Treatment Revenue by Country (2017-2022)
5.2 Americas Female Urinary Incontinence Treatment Sales by Type
5.3 Americas Female Urinary Incontinence Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Female Urinary Incontinence Treatment Sales by Region
6.1.1 APAC Female Urinary Incontinence Treatment Sales by Region (2017-2022)
6.1.2 APAC Female Urinary Incontinence Treatment Revenue by Region (2017-2022)
6.2 APAC Female Urinary Incontinence Treatment Sales by Type
6.3 APAC Female Urinary Incontinence Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Female Urinary Incontinence Treatment by Country
7.1.1 Europe Female Urinary Incontinence Treatment Sales by Country (2017-2022)
7.1.2 Europe Female Urinary Incontinence Treatment Revenue by Country (2017-2022)
7.2 Europe Female Urinary Incontinence Treatment Sales by Type
7.3 Europe Female Urinary Incontinence Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Female Urinary Incontinence Treatment by Country
8.1.1 Middle East & Africa Female Urinary Incontinence Treatment Sales by Country (2017-2022)
8.1.2 Middle East & Africa Female Urinary Incontinence Treatment Revenue by Country (2017-2022)
8.2 Middle East & Africa Female Urinary Incontinence Treatment Sales by Type
8.3 Middle East & Africa Female Urinary Incontinence Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Female Urinary Incontinence Treatment
10.3 Manufacturing Process Analysis of Female Urinary Incontinence Treatment
10.4 Industry Chain Structure of Female Urinary Incontinence Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Female Urinary Incontinence Treatment Distributors
11.3 Female Urinary Incontinence Treatment Customer
12 World Forecast Review for Female Urinary Incontinence Treatment by Geographic Region
12.1 Global Female Urinary Incontinence Treatment Market Size Forecast by Region
12.1.1 Global Female Urinary Incontinence Treatment Forecast by Region (2023-2028)
12.1.2 Global Female Urinary Incontinence Treatment Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Female Urinary Incontinence Treatment Forecast by Type
12.7 Global Female Urinary Incontinence Treatment Forecast by Application
13 Key Players Analysis
13.1 InControl Medical
13.1.1 InControl Medical Company Information
13.1.2 InControl Medical Female Urinary Incontinence Treatment Product Offered
13.1.3 InControl Medical Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 InControl Medical Main Business Overview
13.1.5 InControl Medical Latest Developments
13.2 Uromems
13.2.1 Uromems Company Information
13.2.2 Uromems Female Urinary Incontinence Treatment Product Offered
13.2.3 Uromems Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Uromems Main Business Overview
13.2.5 Uromems Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Female Urinary Incontinence Treatment Product Offered
13.3.3 Johnson & Johnson Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 Coloplast
13.4.1 Coloplast Company Information
13.4.2 Coloplast Female Urinary Incontinence Treatment Product Offered
13.4.3 Coloplast Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Coloplast Main Business Overview
13.4.5 Coloplast Latest Developments
13.5 Boston Scientific
13.5.1 Boston Scientific Company Information
13.5.2 Boston Scientific Female Urinary Incontinence Treatment Product Offered
13.5.3 Boston Scientific Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Boston Scientific Main Business Overview
13.5.5 Boston Scientific Latest Developments
13.6 BD
13.6.1 BD Company Information
13.6.2 BD Female Urinary Incontinence Treatment Product Offered
13.6.3 BD Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 BD Main Business Overview
13.6.5 BD Latest Developments
13.7 Verity Medical
13.7.1 Verity Medical Company Information
13.7.2 Verity Medical Female Urinary Incontinence Treatment Product Offered
13.7.3 Verity Medical Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Verity Medical Main Business Overview
13.7.5 Verity Medical Latest Developments
13.8 Betatech Medical
13.8.1 Betatech Medical Company Information
13.8.2 Betatech Medical Female Urinary Incontinence Treatment Product Offered
13.8.3 Betatech Medical Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Betatech Medical Main Business Overview
13.8.5 Betatech Medical Latest Developments
13.9 CL Medical
13.9.1 CL Medical Company Information
13.9.2 CL Medical Female Urinary Incontinence Treatment Product Offered
13.9.3 CL Medical Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 CL Medical Main Business Overview
13.9.5 CL Medical Latest Developments
13.10 Cousin Surgery
13.10.1 Cousin Surgery Company Information
13.10.2 Cousin Surgery Female Urinary Incontinence Treatment Product Offered
13.10.3 Cousin Surgery Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Cousin Surgery Main Business Overview
13.10.5 Cousin Surgery Latest Developments
13.11 Dipromed
13.11.1 Dipromed Company Information
13.11.2 Dipromed Female Urinary Incontinence Treatment Product Offered
13.11.3 Dipromed Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Dipromed Main Business Overview
13.11.5 Dipromed Latest Developments
13.12 Ethicon
13.12.1 Ethicon Company Information
13.12.2 Ethicon Female Urinary Incontinence Treatment Product Offered
13.12.3 Ethicon Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Ethicon Main Business Overview
13.12.5 Ethicon Latest Developments
13.13 Neomedic International
13.13.1 Neomedic International Company Information
13.13.2 Neomedic International Female Urinary Incontinence Treatment Product Offered
13.13.3 Neomedic International Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Neomedic International Main Business Overview
13.13.5 Neomedic International Latest Developments
13.14 Promedon
13.14.1 Promedon Company Information
13.14.2 Promedon Female Urinary Incontinence Treatment Product Offered
13.14.3 Promedon Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Promedon Main Business Overview
13.14.5 Promedon Latest Developments
13.15 THT Bio-science
13.15.1 THT Bio-science Company Information
13.15.2 THT Bio-science Female Urinary Incontinence Treatment Product Offered
13.15.3 THT Bio-science Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 THT Bio-science Main Business Overview
13.15.5 THT Bio-science Latest Developments
13.16 Condiner Medical
13.16.1 Condiner Medical Company Information
13.16.2 Condiner Medical Female Urinary Incontinence Treatment Product Offered
13.16.3 Condiner Medical Female Urinary Incontinence Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Condiner Medical Main Business Overview
13.16.5 Condiner Medical Latest Developments
14 Research Findings and Conclusion